Craft

Genovis

Stock Price

KR22.5

2024-10-29

Market Capitalization

KR1.4 B

2024-10-28

Revenue

KR128.9 M

FY, 2025

Genovis Summary

Company Summary

Overview
Genovis is a company developing enzymatic tools for the biopharmaceutical industry. It provides SmartEnzymes for the development, production, and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars, and bispecifics. The Genovis SmartEnzymes are used for the digestion, deglycosylation, conjugation of the target molecule.
Type
Public
Status
Active
Founded
1999
HQ
Lund, SE | view all locations
Website
https://www.genovis.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Torben Jørgensen

    Torben Jørgensen, Chairman of the Board of Directors

    • Fredrik Olsson

      Fredrik Olsson, CEO

      • Susanne Ahlberg

        Susanne Ahlberg, General Counsel

        • Rolf Lood

          Rolf Lood, Vice President Research & Development

          LocationsView all

          2 locations detected

          • Lund, Skåne County HQ

            Sweden

          • Cambridge, MA

            United States

            245 First St #1800

          Genovis Financials

          Summary Financials

          Revenue (FY, 2025)
          kr128.9M
          Gross profit (FY, 2025)
          kr115.5M
          Net income (FY, 2025)
          kr23.5M
          Cash (FY, 2025)
          kr163.2M
          EBIT (FY, 2025)
          kr18.6M

          Footer menu